Table 2.
Group |
Platform |
PPA |
NPA |
POA |
no. of positive samples tested |
no. of negative samples tested |
---|---|---|---|---|---|---|
All samples |
Alinity |
81.6 % (CI 95 %=66.6–90.8 %) |
96.4 % (CI 95 %=82.3–99.4 %) |
87.9 % (CI 95 %=77.9–93.7 %) |
38 |
28 |
CN <32 |
Alinity |
100.0 % (CI 95 %=82.4–100.0 %) |
100.0 % (CI 95 %=87.5–100.0 %) |
100.0 % (CI 95 %=92.1–100.0 %) |
18 |
27 |
CN ≥32 |
Alinity |
65.0 % (CI 95 %=43.3–91.9 %) |
96.4 % (CI 95 %=82.3–99.4 %) |
83.3 % (CI 95 %=70.9–91.3 %) |
20 |
28 |
All samples |
ABI |
83.3 % (CI 95 %=66.4–92.7 %) |
97.2 % (CI 95 %=85.8–99.5 %) |
90.9 % (CI 95 %=81.6–95.8 %) |
30 |
36 |
Ct <32 |
ABI |
100.0 % (CI 95 %=67.6–100.0 %) |
100.0 % (CI 95 %=90.1–100.0 %) |
100.0 % (CI 95 %=91.8–100.0 %) |
8 |
35 |
Ct ≥32 |
ABI |
77.3 % (CI 95 %=56.6–89.9 %) |
97.2 % (CI 95 %=85.8–99.5 %) |
89.7 % (CI 95 %=79.2–95.2 %) |
22 |
36 |